|

Venetoclax (VEN) Clinical Trials

2 actively recruiting trials across 1 location

Pipeline

Phase 2: 1Phase 3: 1

Top Sponsors

  • Technische Universität Dresden1
  • Janssen Research & Development, LLC1

Indications

  • Cancer2
  • AML - Acute Myeloid Leukemia1
  • Leukemia, Myeloid, Acute1

Other1 trial

Gilteritinib in Combination With Venetoclax and Azacitidine for AML Patients With FLT3 Mutations Ineligible for Intensive Treatment
Phase 2

Goodyear, Arizona1 trial

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Cancer Treatment Center of America Phoenix

Phase 3

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.